Summary of the LawsuitSummary of the Lawsuit Rosen Law Firm is currently representing investors who purchased shares of common stock or call options, or sold put options, of Altimmune, Inc. (NASDAQ: ALT) between December 1, 2023, and April 26, 2024, in a class action lawsuit. The plaintiffs allege that during this period, the defendants made false or misleading statements about the efficacy and commercial prospects of Altimmune’s lead product candidate, pemvidutide, a glucagon-like peptide-1 (GLP-1) drug for the treatment of obesity. Deadline for Lead Plaintiffs Investors who wish to serve as lead plaintiffs in this class action must request to do so no later than July 5, 2024. Why Rosen Law Firm? Rosen Law Firm is a global investor rights law firm with a proven track record of success in securities class action lawsuits. The firm is ranked No. 1 by ISS Securities Class Action Services for number of securities class action lawsuit settlements in 2017 and has been ranked in the top 4 every year since 2013. Founder Laurence Rosen was named a Titan of Plaintiffs’ Bar by law360 in 2020. How to Join the Class Action Investors can join the class action by visiting https://rosenlegal.com/submit-form/?case_id=22535 or by calling Phillip Kim, Esq. toll-free at 866-767-3653 or emailing [email protected] for class action information. No Class Certification Yet It’s important to note that there is no class certification yet. Until a class is certified, investors are not represented by counsel unless they hire one.
NEW YORK, July 3, 2024 (GLOBE NEWSWIRE) —
WHY: Rosen Law Firm, a global investor rights law firm, reminds those who purchased shares of common stock or purchased call options or sold put options, including shares of common stock purchased or otherwise acquired in connection with the exercise of such options, of Altimmune, Inc. (NASDAQ: ALT) between December 1, 2023 and April 26, 2024, both dates inclusive (the “Class Period”), of the important Deadline for Lead Plaintiffs July 5, 2024.
SO: If you purchased Altimmune securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO: To join the Altimmune class action, go to https://rosenlegal.com/submit-form/?case_id=22535 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for class action information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must request that the Court no later than July 5, 2024A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, companies issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but merely act as intermediaries that refer clients or work with law firms that actually litigate the cases. Choose your attorney wisely. Rosen Law Firm represents investors around the world, concentrating its practice in securities class action lawsuits and shareholder derivative litigation. Rosen Law Firm achieved the largest settlement in a securities class action lawsuit against a Chinese company. Rosen Law Firm was ranked No. 1 by ISS Securities Class Action Services for number of securities class action lawsuit settlements in 2017. The firm has been ranked in the top 4 every year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone, the firm secured more than $438 million for investors. In 2020, founder Laurence Rosen was named a Titan of Plaintiffs’ Bar by law360. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Altimmune overstated the potency of its lead product candidate, pemvidutide, a glucagon-like peptide-1 (“GLP-1”), to differentiate itself from competing GLP-1 agonists based on the drug’s efficacy and tolerability results observed in the evaluation of pemvidutide for the treatment of obesity (the “MOMENTUM Trial”); (2) as a result, the results of the MOMENTUM Trial were less important to the clinical, commercial and competitive prospects of pemvidutide than defendants had led investors to believe; (3) as a result of all of the foregoing, defendants overstated Altimmune’s prospects for finding a strategic partner for the development of pemvidutide; and (4) as a result, Altimmune’s public statements were materially false and misleading at all relevant times. When the actual details came out, the prosecutor claimed that investors had suffered damages.
To join the class action against Altimmune, please visit https://rosenlegal.com/submit-form/?case_id=22535 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for class action information.
There is no class certification. Until a class is certified, you are not represented by counsel unless you hire one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent on serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Lawyer Advertisement. Previous results do not guarantee a similar outcome.
Contact details:
Laurence Rosen, Esq.
Philip Kim, Esq.
The Law Firm of Rosen, PA
275 Madison Avenue, 40th Floor
New York, NY 10016
Phone: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com
